Skip to main content

Remegen

RemeGen Co Ltd is a Chinese commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel biological therapies for autoimmune diseases, oncology, and ophthalmology. The company's antibody-drug conjugate and fusion protein platform has generated key approved therapies including telitacicept for autoimmune disorders and disitamab vedotin for solid tumors. Its R&D operations center on targeted biologics, novel antibody constructs, and specialized clinical trials across China and global markets. Principal revenue is generated from direct commercial sales of approved biologic therapies in Mainland China, alongside upfront collaboration milestone payments and international licensing royalties. RemeGen is a prominent biopharmaceutical innovator in China, holding strategic clinical co-development partnerships with international biopharmaceutical firms. Headquartered in Yantai, China, the company's common stock is dual-listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange STAR Market.

14 of the funds FundTelligence covers report a position in Remegen.

Legal name
Remegen Co. Ltd.
Sector
Health Care
Country
China
Funds holding it
14

Funds holding Remegen

Showing the 8 largest of 14 funds holding it.

Loading...